To determine whether persons living with HIV find a disease-specific advance directive more acceptable than a generic directive.
derstand and appreciate the consequences of treatment decisions (i.e.. when he or she is competent or capable). an advance directive is used at a time when the person has become incompetent or incapable.
Current advance directive documents--for example, the Medical Directive. s Let Me Decide directive, 4 University of Toronto Centre for Bioethics Living Will, s Values History/J or the forms prepared by lawyers and governments--are all generic, Intended for the general public. generic advance directives can be criticized because they contain hypothetical, often irrelevmlt choices and inadequate prognostic information. Compared with generic advance directives, advanced directives designed specifically for people who have a particular disease have several potential advantages, s First. they present patients with choices that are more relevant than those contained in generic advance directives. Second.
because the group of patients completing the advance directive document is more homogenous, more specific prog nostic information cml be presented. Finally. because the patient already has experience of the illness that may lead to those choices, the choices themselves are less hypothet ical. Whether these theorized advantages of disease-specific advance directives are borne out in practice is currently unknown.
The purpose of this study was to determine whether persons living with HIV find a disease specific HIV advance directive more acceptable than a generic advance directive.
METHODS

Study Design
In this randomized trial, participants were random ized to one of three groups: a group receiving the generic Centre for Bioethics Living Will alone, a group receiving the disease specific HIV Living Will alone, or a group re ceiving both of these advmlce directives. Participants were followed over two visits, At the first visit, participmlts were screened for eligibility, received information about the study, provided consent to participate in the research, viewed a 17-minute educational video about advance directives developed specifically for persons with HIV, and received the generic Centre for Bioethics Living Will alone, the diseasespecific HIV Living Will alone, or both advance directives to review at home. At the second visit (2 weeks later), par ticipmlts completed the advance directive they had received 729
(those subjects randomized to receive both advance direc tires completed the one they preferred), and rated the acceptability of the advance directive (those randomized to receive both advance directives rated both). Participants were enrolled between November 1. 1994. and June 15. 1995.
Participants
A volunteer sample of persons with HIV responded to the study advertisements or posters distributed in the community by the AIDS Committee of Toronto and placed in the waiting rooms of the Toronto Hospital Immunodefl ciency Clinic. In addition, patients attending the Inmmnodeficiency Clinic were given information about the study and a telephone number to call if they were interested in participating, During the study period, the charts of all patients at the Immunodeficiency Clinic had study labels on which to note if a patient had been given the study in formation, chose not to participate, or had been excluded, Participants were excluded if they were less than 16 years old, were not fluent in English, could not read, were inca pable of completing an advance directive (as measured by a Standardized Mini-Mental Status Evaluation [SMMSE] test score < 23), would experience undue emotional dis tress from completing an advmlce directive (as measured by self-report), resided outside Metropolitml Toronto. or refused participation in the research. A log of rejected participants documenting reasons for exclusion and refusals was kept, At the Toronto Hospital Immunodeflciency Clinic, there were 753 patients being followed during the study period. Of these. 268 did not attend the clinic during the study period, 200 were not approached (reason not identi fled), and 70 were excluded by clinic staff (41 were too ill. 20 were unable to read or understand English well. 3 were mentally incapable, and 6 were excluded by clinic staff for unidentified reasons). The remaining 215 patients were approached by the clinic staff or the study co ordinator and given information about the study. Of these. 41 were satisfied with a previously completed advance directive and chose not to participate, 9 lived ou~ side the study area, 12 had entered the study through the AIDS Committee of Toronto. 1 scored below 22 on the SMMSE, 6 refused, and 40 did not contact the study co ordinator. The remaining 106 patients participated in the study, but 2 withdrew, leaving a total of 104 participants who completed the study through this site. The AIDS Corn mittee of Toronto received 114 referrals. Of these, 5 de cided not to participate. 5 withdrew. 3 were too ill to participate, 1 did not read or understand English, 1 was unable to read, and 99 completed the study. Therefore, at both sites, a total of 203 participants completed the study,
Interventions
Two advance directives were used in this study: the 
Outcome Measures
Acceptability of the advance directives used in the study was measured using the Advance Directive Choice The height of e a c h bar represents t h e proportion of participants at the second interview w h o w a n t e d the specified treatn-,er,t it, the specified t-,eoltt-, situatior,. The r,ur,-,ber of participants an- Questionnaire (ADCQ) and Advance Directive AcceptabilIty Questionnaire (ADAQ). The ADCQ asks respondents, "We are interested in which of the two living wills you liked best. If you had to choose one of these two living wills, which one would you choose to complete?" It also elicits the reasons for their choice. The ADAQ contains 14 items rated on a 5-polnt ordinal scale from excellent to poor. The ADAQ was initially used in a previous study and subsequently modified on the basis of results of factor analysis and open-ended responses by participants. > It has been evaluated for face or content validity by an Interdisciplinary panel of e x p e l s : of 22 respondents, 19 (86%) said the ADAQ fulfilled its stated purpose and 3
[14%) said it did not; the current version of the ADAQ Incorporates the suggestions of these experts. In a prevlous study. Internal consistency reliability of the ADAQ measured using Cronhach's ~ was (,.9:3.
Data Analysis
The proportion of participants who preferred each advance directive was compared using the :ta test. The total score on the ADAQ was calculated a s the s u m of the individual items and reported as a percentage of the highest achievable score. These scores were analyzed using repeated measures data analysis by the Proc Mb:ed proce- ducted. As this factor or its interaction with the main effect of advance directive type did not prove to be a significant confounder, the analysis was simplified to model only the main effect of advance directive type on total ADAQ score.
JGIM
As well. we recorded and described, using content analysis, participants' open ended responses regarding why they preferred one or the other advance directive.
RI:SU LTS
Participant Characteristics
The characteristics of the 203 participants are shown in Table 1 . There were no significmlt differences at baseline among the three groups.
Treatment Preferences
Treatment preferences recorded in the Centre for Bioethics Living Will and the H1V Living Will by the end of the second interview are shown in Figures 1 and 2 . As shown in Figures 1 and 2 . health states mid severity of illness have a greater influence on preferences than do treat ments, For instance, preferences across health states in the Centre for Bioethics Living Will vary widely from 84% of respondents wanting cardiopulmonary resuscitation (CPR) in their current health state to 7% wmlting CPR in permanent coma. Moreover. 69% of respondents would want CPR in mild dementia, 37% in moderate dementia, and 8% in severe dementia, By contrast, in current health, the range of preferences is from 84% of respondents wanting CPR to 9 7% wanting antibiotics.
Acceptability of the Advance Directives
Of the 203 participmKs. 50 received the generic Centre for Bioethics Living Will alone, 52 received the disease specific HIV Living Will alone, and 101 received both advance directives, Of the 101 participants who received both when asked. "If you had to choose one of these two living wills, which one would you choose to complete?," 78 (77.2%) preferred the H1V Living Will and 23 (22.8%) pre ferred the generic Centre for Bioethics Living Will (p < .001: reject null hypothesis that p = q = .5). Of the 78 participants who chose the disease specific H1V Living Will. 72 did so because it was more specific or relevant to their situation (for instance, participants said the H1V Liv ing Will "related to my situation without irrelevant ver biage." "seems more appropriate to my care." "zeros in on specific treatments relating to AIDS/H1V," "pertains to the possible problems that might arise"): 5 said the H1V Living Will was more specific but they would add "stroke and other chronic conditions": and 1 wanted "more control." Of the 23 participants who chose the generic Centre for Bioethics Living Will. 20 did so because it was more detailed or comprehensive (for instance, one participant said, "H1V positive people also get strokes, car accidents, etc,"): one participant did not want his family to know he had H1V: one was concerned about the potential for dis crimination against people with H1V: and one said it was the "lesser of two evils,"
The mean ADAQ score was 68.5% for the H1V Living Will and 66.2% for the Centre for Bioethics Living Will (F = 3.9. p ,0510), The acceptability ratings for the individual item scores for the two advance directives are shown in Table 2 . Most of the ratings were in the very good to good range,
DISCUSSION
The major finding of this study is that persons with HIV preferred a disease specific advance directive over a generic one, This preference was shown in two ways---based on a Fend toward higher ADAQ scores for the disease specific advance directive. The disease-specific advmlce directive was preferred because it was more specific and relevant to persons with HIV. This study confirms that the theorized advantages of disease-specific advance directives ~ are borne out in practice, at least for patients with HIV.
Persons with HIV who wish to complete an advance directive should be offered a disease-specific HIV advance directive. This recommendation is consistent with previ ous studies, which have shown that people prefer detailed advance directives, u that general instructions are not helpful in communicating patient wishes regarding spe cific life sustaining procedures, l~ and that more specific advance directives result in more uniform interpretation by physicians, is Although some might argue that accept ability is a weak foundation on which to base such a rec onmlendation, we believe that the most important effects of advance directives and advance care planning are not on those clinical and financial outcomes that have been measured to date. 14 but rather on psychosocial outcomes related to people preparing for death and dying, is Our findings should also encourage investigators to develop and evaluate specific advance directives for other diseases such as cancer and Alzheimer disease.
The pattern of treatment preferences has implications for the design of generic advance directives and physicimlpatient discussions. As shown in Figures 1 and 2 , health states and severity of illness have a greater influence on preferences than do treatments, The same pattern of treatment preferences was previously documented in pm tients undergoing hemodialysis. ' -~ To elicit a full set of pref erences, advance directives should focus on descriptions of a spectrum of health states, and the descriptions of these health states should be at least as comprehensive as the description of treatments, In discussions with patients about future treatment choices, such as discus sions about "Do not resuscitate" orders, physicians should focus on the resultant health states as well as the treatments proposed. Moreover, an advance directive or physi clan patient discussion that does not probe for diffe~ ences in illness severity within health states will miss major variations in preferences. Our study did not explic itly examine how the duration of life sustaining trea~ ment, a factor that is probably also important, influences the pattern of treatment preferences.
Disease specific advance directives have one major disadvantage compared with generic advance directives, Although disease specific advance directives focus on the most likely future situations for patients with a particular disease, unlikely events sometimes occur. Persons living with HIV may still have a stroke or automobile accident, as was pointed out by our participants. In addition, an un anticipated and unintended problem with disease-specific advance directives in the context of HIV is the issue of confidentiality. Of those who preferred the generic Centre for Bioethics Living Will, one participant did so because of confidentiality concerns. Two other participants men tioned this as well, although it was not the primary rea son they chose the generic advmlce directive. The issue of confidentiality could be addressed, in part, by not writing "HIV" on the cover of the living will.
Our study also provides a description of treatment preferences of persons living with HIV. For instance, 87% of respondents would want to receive antibiotics, and 64% would wmlt to be put on a ventilator, in the acute or potentially reversible illness scenario in the HIV Living Will. These findings are consistent with those of Stein brook et al,, who found that 95% of patients with AIDS wanted antibiotic treatment and 55% wanted mechanical ventilation for Pneumocys tis carinti pneumonia, is Eighteen percent of the participants in our study said they had previously completed an advance directive. This is consistent with previous studies of persons living with HIV, which found that 28% had completed an advance directive, 17 and 38% had discussed their life sustaining treatment preferences with their physician, zs The rate of completion of advmlce directives by patients with HIV is considerably higher than the 2% rate among general in ternal medicine outpatients at the same hospital, 1, _~ or the 12% rate among the Ontario PublicY n
The main potential limitation of this study is volun teer bias. Participants were not randomly sampled but volunteered in response to advertisements, This bias does not undermine the main conclusion because participants were randomized to receive one or the other (or both) ad vmlce directives. The bias does limit the generalizability of the findings to those who would complete an advance di rective, but these are precisely the people for whom ad vmlce directive forms are designed, In addition, the generalizability of our findings is limited by our use of one specific patient population~ersons living with HIV and by the observation that advance directive documents are only one element of advance care planning, a "process of communication among patients, their health care provid ers. their families, and important others regarding the kind of care that will be considered appropriate when the patient cannot make decisions. '';1
In conclusion, persons living with HIV prefer a diseasespecific to a generic advance directive. They should be o5 fered a disease specific advance directive.
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